Todos os estudos
RecrutamentoFASE3INTERVENCIONISTA

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

This study is testing a medicine called guselkumab in children and teenagers (aged 2 to 17) who have moderately to severely active Crohn's disease. Crohn's disease can cause inflammation in the gut, leading to symptoms like tummy pain and frequent toilet trips. The main aim is to see how effective guselkumab is over 52 weeks (about one year) for patients who showed improvement in their symptoms after the first 12 weeks of treatment. Researchers will use special tests, like internal cameras (endoscopy), to check the healing of the gut lining. This is a Phase 3 study, meaning it's a larger trial happening after initial safety and effectiveness tests, bringing it closer to potentially being available to more patients.

Em resumo

Status
Recrutamento
Fase
FASE3
Patrocinador
Janssen Pesquisa & Desenvolvimento, LLC
Meta de inscrição
120
Iniciar
13 de mar de 2024
Conclusão estimada
14 Aug 2028

Sobre o que é este estudo?

Crohn's disease is a condition that causes long-term inflammation in your digestive system. This can lead to symptoms like tummy pain, diarrhoea, weight loss, and feeling very tired. For some children and teenagers, these symptoms can be quite severe and impact their daily lives.

This particular study is looking into a medicine called guselkumab. It’s being tested in young people aged 2 to 17 who have Crohn’s disease that isn't well controlled by other treatments, or who haven't been able to tolerate them. The study wants to find out if guselkumab can effectively reduce the inflammation and symptoms caused by Crohn’s after one year of treatment, especially for those who show early improvement.

The researchers will be monitoring participants closely to see how well the medicine helps heal the gut lining. This information is important because it could help doctors understand if guselkumab is a safe and effective new option for treating Crohn's disease in young people in the future.

Pontos principais

  • This study is for children and teenagers (2-17 years old) with Crohn's disease.
  • It tests a medicine called guselkumab over one year.
  • Aims to see if it helps reduce symptoms and heal the gut lining.
  • It's for those whose current treatments haven't worked well.
  • Participants will have regular medical check-ups and tests.

Quem pode ser elegível?

To join this study, you (or your child) must have been diagnosed with Crohn's disease that currently causes moderate to severe symptoms. Doctors will confirm this using a special scoring system and internal camera tests (endoscopy) to check for active inflammation in the gut.

You would also need to have tried other common treatments for Crohn's disease in the past, such as certain immune-suppressing medicines or steroids, and either they didn't work well enough, stopped working, or caused too many side effects. Alternatively, you might be eligible if you've developed a dependency on steroid medication, or if nutritional therapy hasn't been effective.

However, some things would mean you can't take part. For example, if your Crohn's disease has caused complications like blockages in the gut that might need surgery soon, or if you have an abscess (a collection of pus). You also couldn't join if you’ve had certain types of bowel surgery in the last few months.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. I have been diagnosed with Crohn's disease.
  2. My Crohn's disease currently causes moderate to severe symptoms.
  3. I have tried other Crohn's medicines (like immune suppressors or steroids) and they didn't work well, stopped working, or caused bad side effects.
  4. I haven't had any recent surgeries on my bowel (within the last few months).
  5. I do not have any abscesses or severe bowel blockages due to Crohn's.
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part in this study, you would first go through some checks to make sure the study is right for you. This might involve physical exams, blood tests, and an endoscopy (a procedure where a thin, flexible tube with a camera is used to look inside your digestive system) to confirm the level of activity of your Crohn's disease. If you qualify, you or your child would then receive the study medication, guselkumab. The exact way this medicine is given (e.g., by injection) and how often would be explained to you in detail by the study team. You would have regular visits to the clinic for assessments, which include checking your symptoms, blood tests, and sometimes further endoscopies. The study aims to follow how you respond to the treatment over 52 weeks (about one year).

Riscos e benefícios potenciais

Taking part in this study may offer potential benefits, such as receiving a new investigational treatment for your Crohn’s disease that might improve your symptoms and gut health. However, like all medicines, guselkumab could have side effects, and some might not be known yet. The study team will monitor you closely for any unwanted effects. You have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (85)

  • Centro Médico Cedars Sinai
    Código postal verificado
    Los Angeles, Estados Unidos· Recrutamento
  • Connecticut Children's Medical Center
    Código postal verificado
    Hartford, Estados Unidos· Concluído
  • Universidade Emory
    Código postal verificado
    Atlanta, Estados Unidos· Recrutamento
  • Children's Center for Digestive Health Care
    Código postal verificado
    Atlanta, Estados Unidos· Recrutamento
  • Riley Hospital for Children
    Código postal verificado
    Indianápolis, Estados Unidos· Concluído
  • Boston Childrens Hospital
    Código postal verificado
    Boston, Estados Unidos· Recrutamento
  • Goryeb Children's Hospital
    Código postal verificado
    Morristown, United States· Recrutamento
  • Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center
    Código postal verificado
    Nova Iorque, Estados Unidos· Recrutamento
  • Icahn School of Medicine at Mount Sinai
    Código postal verificado
    Nova Iorque, Estados Unidos· Recrutamento
  • Centro Médico da Universidade de Columbia
    Código postal verificado
    Nova Iorque, Estados Unidos· Concluído
  • The Children's Medical Center of Dayton
    Código postal verificado
    Dayton, United States· Concluído
  • Hospital Infantil da Filadélfia
    Código postal verificado
    Filadélfia, Estados Unidos· Recrutamento

Perguntas frequentes

O que é guselkumabe?

Guselkumab is an investigational medicine being tested to see if it can help reduce inflammation in Crohn’s disease.

Quanto tempo durará o estudo?

The main part of this study will last for about 52 weeks, which is roughly one year.

Will I know if I'm getting the active medicine or a placebo?

The study design will be explained fully by the research team; in some phases of trials, it's common for participants to receive the active drug rather than a placebo in studies of this type.

What happens if guselkumab doesn't work for me?

The study team will regularly monitor your condition, and if the treatment isn't working or your condition worsens, they will discuss your options for further care.

Eu tenho que pagar para participar do estudo?

No, all study-related treatments and assessments are usually provided free of charge.

Como saber mais

Contato para Estudo

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Study of Guselkumab in Pediatric Participants With Moderat…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.